TEMPUS AI INC-CL A (TEM) Fundamental Analysis & Valuation

NASDAQ:TEM • US88023B1035

52.26 USD
-0.79 (-1.49%)
At close: Mar 6, 2026
51.9643 USD
-0.3 (-0.57%)
After Hours: 3/6/2026, 8:00:02 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This TEM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to TEM. TEM was compared to 57 industry peers in the Life Sciences Tools & Services industry. TEM may be in some trouble as it scores bad on both profitability and health. TEM is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

2

1. TEM Profitability Analysis

1.1 Basic Checks

  • In the past year TEM has reported negative net income.
  • In the past year TEM has reported a negative cash flow from operations.
  • In the past 5 years TEM always reported negative net income.
  • TEM had a negative operating cash flow in each of the past 5 years.
TEM Yearly Net Income VS EBIT VS OCF VS FCFTEM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -200M -400M -600M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -10.77%, TEM is in line with its industry, outperforming 47.37% of the companies in the same industry.
  • With a Return On Equity value of -49.87%, TEM is not doing good in the industry: 70.18% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -10.77%
ROE -49.87%
ROIC N/A
ROA(3y)-46.17%
ROA(5y)-49.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TEM Yearly ROA, ROE, ROICTEM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 0 -500 -1K

1.3 Margins

  • Looking at the Gross Margin, with a value of 62.74%, TEM belongs to the top of the industry, outperforming 84.21% of the companies in the same industry.
  • In the last couple of years the Gross Margin of TEM has grown nicely.
  • TEM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.74%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.61%
GM growth 5Y32.65%
TEM Yearly Profit, Operating, Gross MarginsTEM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. TEM Health Analysis

2.1 Basic Checks

  • TEM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • TEM has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, TEM has more shares outstanding
  • Compared to 1 year ago, TEM has a worse debt to assets ratio.
TEM Yearly Shares OutstandingTEM Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
TEM Yearly Total Debt VS Total AssetsTEM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • An Altman-Z score of 2.33 indicates that TEM is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.33, TEM is doing good in the industry, outperforming 64.91% of the companies in the same industry.
  • TEM has a Debt/Equity ratio of 2.52. This is a high value indicating a heavy dependency on external financing.
  • TEM has a worse Debt to Equity ratio (2.52) than 87.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.52
Debt/FCF N/A
Altman-Z 2.33
ROIC/WACCN/A
WACC10.8%
TEM Yearly LT Debt VS Equity VS FCFTEM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • TEM has a Current Ratio of 3.13. This indicates that TEM is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.13, TEM is in line with its industry, outperforming 56.14% of the companies in the same industry.
  • TEM has a Quick Ratio of 3.00. This indicates that TEM is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 3.00, TEM perfoms like the industry average, outperforming 57.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.13
Quick Ratio 3
TEM Yearly Current Assets VS Current LiabilitesTEM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. TEM Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 75.89% over the past year.
  • Looking at the last year, TEM shows a very strong growth in Revenue. The Revenue has grown by 83.41%.
  • The Revenue has been growing by 46.57% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)75.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
Revenue 1Y (TTM)83.41%
Revenue growth 3Y58.29%
Revenue growth 5Y46.57%
Sales Q2Q%82.98%

3.2 Future

  • TEM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 47.75% yearly.
  • TEM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 21.15% yearly.
EPS Next Y23.65%
EPS Next 2Y38.37%
EPS Next 3Y44%
EPS Next 5Y47.75%
Revenue Next Year25.88%
Revenue Next 2Y23.76%
Revenue Next 3Y22.04%
Revenue Next 5Y21.15%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TEM Yearly Revenue VS EstimatesTEM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 1B 2B 3B 4B
TEM Yearly EPS VS EstimatesTEM Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 6

More info and screens

Find the best growth stocksShow best growing peers

1

4. TEM Valuation Analysis

4.1 Price/Earnings Ratio

  • TEM reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TEM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TEM Price Earnings VS Forward Price EarningsTEM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TEM Per share dataTEM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • TEM's earnings are expected to grow with 44.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.37%
EPS Next 3Y44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. TEM Dividend Analysis

5.1 Amount

  • No dividends for TEM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TEM Fundamentals: All Metrics, Ratios and Statistics

TEMPUS AI INC-CL A

NASDAQ:TEM (3/6/2026, 8:00:02 PM)

After market: 51.9643 -0.3 (-0.57%)

52.26

-0.79 (-1.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-24
Earnings (Next)05-01
Inst Owners54.06%
Inst Owner Change6.71%
Ins Owners8.12%
Ins Owner Change0.57%
Market Cap9.34B
Revenue(TTM)1.27B
Net Income(TTM)-245.03M
Analysts77.39
Price Target88.09 (68.56%)
Short Float %21.59%
Short Ratio4.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.19%
Min EPS beat(2)5.3%
Max EPS beat(2)35.09%
EPS beat(4)4
Avg EPS beat(4)16.89%
Min EPS beat(4)5.3%
Max EPS beat(4)35.09%
EPS beat(8)7
Avg EPS beat(8)3.83%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)0.51%
Min Revenue beat(2)0.36%
Max Revenue beat(2)0.66%
Revenue beat(4)4
Avg Revenue beat(4)2%
Min Revenue beat(4)0.36%
Max Revenue beat(4)4.94%
Revenue beat(8)5
Avg Revenue beat(8)0.85%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.47%
PT rev (3m)-4.41%
EPS NQ rev (1m)-13.03%
EPS NQ rev (3m)-21.43%
EPS NY rev (1m)0.59%
EPS NY rev (3m)7.69%
Revenue NQ rev (1m)0.33%
Revenue NQ rev (3m)0.52%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)0.47%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.35
P/FCF N/A
P/OCF N/A
P/B 19.01
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.47
Fwd EYN/A
FCF(TTM)-1.37
FCFYN/A
OCF(TTM)-1.22
OCFYN/A
SpS7.11
BVpS2.75
TBVpS-1.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -10.77%
ROE -49.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.74%
FCFM N/A
ROA(3y)-46.17%
ROA(5y)-49.49%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y15.61%
GM growth 5Y32.65%
F-Score4
Asset Turnover0.56
Health
Industry RankSector Rank
Debt/Equity 2.52
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.65%
Cap/Sales 2.14%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.13
Quick Ratio 3
Altman-Z 2.33
F-Score4
WACC10.8%
ROIC/WACCN/A
Cap/Depr(3y)63.29%
Cap/Depr(5y)59.91%
Cap/Sales(3y)3.95%
Cap/Sales(5y)4.43%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%77.78%
EPS Next Y23.65%
EPS Next 2Y38.37%
EPS Next 3Y44%
EPS Next 5Y47.75%
Revenue 1Y (TTM)83.41%
Revenue growth 3Y58.29%
Revenue growth 5Y46.57%
Sales Q2Q%82.98%
Revenue Next Year25.88%
Revenue Next 2Y23.76%
Revenue Next 3Y22.04%
Revenue Next 5Y21.15%
EBIT growth 1Y63.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year222.89%
EBIT Next 3Y86.11%
EBIT Next 5Y73.77%
FCF growth 1Y-16.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.36%
OCF growth 3YN/A
OCF growth 5YN/A

TEMPUS AI INC-CL A / TEM FAQ

What is the fundamental rating for TEM stock?

ChartMill assigns a fundamental rating of 3 / 10 to TEM.


Can you provide the valuation status for TEMPUS AI INC-CL A?

ChartMill assigns a valuation rating of 1 / 10 to TEMPUS AI INC-CL A (TEM). This can be considered as Overvalued.


What is the profitability of TEM stock?

TEMPUS AI INC-CL A (TEM) has a profitability rating of 2 / 10.


What is the earnings growth outlook for TEMPUS AI INC-CL A?

The Earnings per Share (EPS) of TEMPUS AI INC-CL A (TEM) is expected to grow by 23.65% in the next year.